Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer.
Mack KN, Bauer D, Carter LM, Carrasco SE, Atmane MI, Viray TD, Brooks CL, Hollingsworth MA, Radhakrishnan P, Lewis JS.
Mack KN, et al. Among authors: carter lm.
Nucl Med Biol. 2024 Nov 22;140-141:108976. doi: 10.1016/j.nucmedbio.2024.108976. Online ahead of print.
Nucl Med Biol. 2024.
PMID: 39615062